Mycobacterium szulgai: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
Line 17: Line 17:
==Treatment==
==Treatment==
===Antimicrobial regimen===
===Antimicrobial regimen===
* in vitro susceptibility<ref>{{Cite journal| doi = 10.1164/rccm.200604-571ST| issn = 1073-449X| volume = 175| issue = 4| pages = 367–416| last1 = Griffith| first1 = David E.| last2 = Aksamit| first2 = Timothy| last3 = Brown-Elliott| first3 = Barbara A.| last4 = Catanzaro| first4 = Antonino| last5 = Daley| first5 = Charles| last6 = Gordin| first6 = Fred| last7 = Holland| first7 = Steven M.| last8 = Horsburgh| first8 = Robert| last9 = Huitt| first9 = Gwen| last10 = Iademarco| first10 = Michael F.| last11 = Iseman| first11 = Michael| last12 = Olivier| first12 = Kenneth| last13 = Ruoss| first13 = Stephen| last14 = von Reyn| first14 = C. Fordham| last15 = Wallace| first15 = Richard J.| last16 = Winthrop| first16 = Kevin| last17 = ATS Mycobacterial Diseases Subcommittee| last18 = American Thoracic Society| last19 = Infectious Disease Society of America| title = An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases| journal = American Journal of Respiratory and Critical Care Medicine| date = 2007-02-15| pmid = 17277290}}</ref>
* '''1. in vitro susceptibility'''<ref>{{Cite journal| doi = 10.1164/rccm.200604-571ST| issn = 1073-449X| volume = 175| issue = 4| pages = 367–416| last1 = Griffith| first1 = David E.| last2 = Aksamit| first2 = Timothy| last3 = Brown-Elliott| first3 = Barbara A.| last4 = Catanzaro| first4 = Antonino| last5 = Daley| first5 = Charles| last6 = Gordin| first6 = Fred| last7 = Holland| first7 = Steven M.| last8 = Horsburgh| first8 = Robert| last9 = Huitt| first9 = Gwen| last10 = Iademarco| first10 = Michael F.| last11 = Iseman| first11 = Michael| last12 = Olivier| first12 = Kenneth| last13 = Ruoss| first13 = Stephen| last14 = von Reyn| first14 = C. Fordham| last15 = Wallace| first15 = Richard J.| last16 = Winthrop| first16 = Kevin| last17 = ATS Mycobacterial Diseases Subcommittee| last18 = American Thoracic Society| last19 = Infectious Disease Society of America| title = An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases| journal = American Journal of Respiratory and Critical Care Medicine| date = 2007-02-15| pmid = 17277290}}</ref>
:* M. szulgai is susceptible in vitro to most antituberculous drugs including [[Quinolones]] and newer [[Macrolides]]
:* M. szulgai is susceptible in vitro to most antituberculous drugs including [[Quinolones]] and newer [[Macrolides]].


* Pulmonary infection
* '''2. Pulmonary infection'''
:* Preferred regimen: three- to four-drug regimen that includes 12 months of negative sputum cultures while on therapy
:* Preferred regimen: three- or four-drug regimen that includes 12 months of negative sputum cultures while on therapy


* Extrapulmonary infection
* '''3. Extrapulmonary infection'''
:* Preferred regimen: combination antituberculous medication based on in vitro susceptibilities for 4 to 6 months
:* Preferred regimen: combination antituberculous medications based on in vitro susceptibilities for 4 to 6 months


==References==
==References==

Revision as of 16:54, 7 July 2015

style="background:#Template:Taxobox colour;"|Mycobacterium
style="background:#Template:Taxobox colour;" | Scientific classification
Kingdom: Bacteria
Phylum: Actinobacteria
Order: Actinomycetales
Suborder: Corynebacterineae
Family: Mycobacteriaceae
Genus: Mycobacterium
Species: M. szulgai

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mycobacterium szulgai is a species of Mycobacterium. It is a Scotochromogen and is currently ungrouped. It is known to cause skin infections.[1]

Treatment

Antimicrobial regimen

  • 1. in vitro susceptibility[2]
  • M. szulgai is susceptible in vitro to most antituberculous drugs including Quinolones and newer Macrolides.
  • 2. Pulmonary infection
  • Preferred regimen: three- or four-drug regimen that includes 12 months of negative sputum cultures while on therapy
  • 3. Extrapulmonary infection
  • Preferred regimen: combination antituberculous medications based on in vitro susceptibilities for 4 to 6 months

References

  1. Hizawa K, Nagata Y, Kudo T, Taniguchi M, Matsumoto T, Iida M (September 2009). "[A case of steroid-dependent ulcerative colitis complicated by skin infection of Mycobacterium szulgai]". Nippon Shokakibyo Gakkai Zasshi (in Japanese). 106 (9): 1359–63. PMID 19734708.
  2. Griffith, David E.; Aksamit, Timothy; Brown-Elliott, Barbara A.; Catanzaro, Antonino; Daley, Charles; Gordin, Fred; Holland, Steven M.; Horsburgh, Robert; Huitt, Gwen; Iademarco, Michael F.; Iseman, Michael; Olivier, Kenneth; Ruoss, Stephen; von Reyn, C. Fordham; Wallace, Richard J.; Winthrop, Kevin; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America (2007-02-15). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". American Journal of Respiratory and Critical Care Medicine. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. ISSN 1073-449X. PMID 17277290.